CVM Latest Press Releases

-- November 10, 2026 --

CEL-SCI's Dr. Eyal Talor Receives Second International Keynote Invitation on Multikine Head and Neck Cancer Research Business Wire 9:04 AM

-- October 26, 2026 --

CEL-SCI Presents New Phase 3 Multikine Data at World Congress: Pre-Surgical Biomarkers Identify Head & Neck Cancer Patients Achieving 73% 5-Year Survival Business Wire 8:00 AM

-- September 15, 2026 --

CEL-SCI Invited to Deliver Keynote Address on Multikine at 6th World Congress on Otology, Rhinology and Laryngology Business Wire 8:37 AM

-- August 17, 2026 --

CEL-SCI Reports Fiscal Third Quarter 2026 Results Business Wire 8:30 AM

-- August 4, 2026 --

CEL-SCI Study Published in Peer-Reviewed Oral Oncology Supports Multikine's Biomarker Strategy and Potential Overall Survival Benefit Ahead of Head and Neck Cancer Confirmatory Registration Study Business Wire 8:00 AM

-- July 30, 2026 --

Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients Business Wire 8:31 AM

-- July 13, 2026 --

CEL-SCI to Launch FDA Registration-Enabling Phase 3 Confirmatory Study to Bring Multikine to Market for Newly Diagnosed Head and Neck Cancer Business Wire 8:00 AM

-- June 24, 2026 --

CEL-SCI and Saudi Amarox Hold Strategic Agreement Signing Ceremony at BIO 2026, Advancing U.S.-Saudi Cooperation in Cancer Care Business Wire 8:00 AM

-- June 16, 2026 --

CEL-SCI Announces Closing of Offering Business Wire 4:01 PM

CEL-SCI Advances Multikine Immunotherapy for Head and Neck Cancer Through Dual U.S. Registration Study and Saudi Market Entry Strategy Business Wire 8:00 AM

Market Data Delayed 15 Minutes